

July 30, 2025

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot no. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

Scrip Code: 543349

NSE Symbol: ACUTAAS

Subject: Unaudited Standalone & Consolidated Financial Results for the First Quarter ended June 30, 2025

We would like to inform that the Board of Directors at its meeting held on July 30, 2025 inter alia, considered and approved the Unaudited Standalone and consolidated Financial Results for the first quarter ended June 30, 2025 as recommended by the Audit Committee.

The Board also took note of the 'Limited Review Report' issued by the Company's Statutory Auditors, M/s. Maheshwari & Co. Chartered Accountants. We enclose herewith copy of the Unaudited Financial Results (Standalone and Consolidated) for the first quarter ended June 30, 2025 and the said Limited Review Report.

As required under Regulation 47 (1) (b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the extract of the Financial Results will be published in the newspapers in the format prescribed by SEBI. The Financial Results will also be available on the Company's website at www.acutaas.com

Kindly take above as compliance of Regulation 33 and 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 11.30 a.m. and concluded at **01.25 PM**

Thanking you,
Yours faithfully,

For, ACUTAAS CHEMICALS LIMITED

Ekta Kumari Srivastava
Company Secretary & Compliance Officer
Encl: As above



Independent Auditor's Review Report on Unaudited Consolidated Financial Results of Acutaas Chemicals Limited for the Quarter ended June 30, 2025 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Acutaas Chemicals Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Acutaas Chemicals Limited ('hereinafter referred to as 'the Parent') and its subsidiaries (the parent and its subsidiaries together referred to as "the Group") and its joint venture for the quarter ended June 30, 2025 (the 'Statement'), attached herewith, being submitted by the Parent pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Regulations)
2. This Statement which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') as amended, read with relevant rules issued thereunder ('Ind AS 34') and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The statement includes the results of the following entities:
 - a. Holding Company: Acutaas Chemicals Limited
 - b. Wholly owned Subsidiary Company: Ami Organics Electrolytes Private Limited, now known as 'Acutaas Chemicals Electrolytes Private Limited'
 - c. Wholly owned Subsidiary Company: Baba Advance Materials Limited, now known as 'Acutaas Advance Material Limited'
 - d. Subsidiary: Baba Fine Chemicals (Partnership Firm)
 - e. Step down subsidiary: Enchem Ami Organics Private Limited
 - f. Joint Venture: Ami Onco-Theranostics, LLC

Office: 1302/1303, Solaris One, Vijay Nagar, Opp. Teli Gali, Andheri (East), 400069

Head office: 10-11, Third Floor, Esplanade Building, 3 A K Naik Marg (Bestian Road), Near New Empire Cinema, Fort, CST, Mumbai 400 001
Tel.: +91-22-22077472/22072620, E-mail: info@maheshwariandco.in, Website: www.maheshwariandco.in

5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.

Chartered Accountants

Firm's Registration No.: 105834W



Vikas Asawa

(Partner)

(Membership No.: 172133)

UDIN: 25172133BMIABF1627



Place: Mumbai

Date: July 30, 2025



ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Consolidated Unaudited Financial Results for the Quarter Ended on June 30, 2025


(₹ in Lakhs, unless otherwise stated)

Particulars	Quarter Ended			Year Ended
	June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
	Unaudited	Unaudited	Unaudited	Audited
Income				
Revenue from operations	20,723.72	30,848.34	17,667.09	100,687.55
Other income	1,593.77	577.91	104.26	1,692.94
Total Income	22,317.49	31,426.25	17,771.35	102,380.49
Expenses				
Cost of materials consumed	10,406.01	16,455.18	10,505.51	56,981.13
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(716.98)	(206.86)	(272.23)	(1,762.96)
Employee benefits expense	2,507.33	2,330.12	1,905.60	8,365.59
Finance costs	63.85	60.32	442.64	621.84
Depreciation and amortization expense	813.08	729.82	617.92	2,662.14
Other expenses	3,436.63	3,774.23	2,576.48	13,896.45
Total expenses	16,509.92	23,142.81	15,775.92	80,764.19
Profit before exceptional items and tax	5,807.57	8,283.44	1,995.43	21,616.30
Exceptional items	-	-	-	-
Profit before tax	5,807.57	8,283.44	1,995.43	21,616.30
Tax expense				
Current tax	1,272.82	1,550.58	453.35	4,918.95
Deferred tax	133.70	461.25	73.11	655.58
Total tax expense	1,406.52	2,011.83	526.46	5,574.53
Profit for the period	4,401.05	6,271.61	1,468.97	16,041.77
Other comprehensive income				
Items that will not be reclassified to profit or loss				
Remeasurement of defined employee benefit plans	(4.37)	40.34	(1.25)	(17.48)
Tax impact on items that will not be reclassified to profit or loss	0.92	(10.90)	-	3.67
Total Other Comprehensive Income (net of tax)	(3.45)	29.44	(1.25)	(13.81)
Total comprehensive income for the period	4,397.60	6,301.05	1,467.72	16,027.96
Profit attributable to				
Owners of the company	4,429.34	6,248.28	1,394.53	15,871.36
Non-controlling interest	(28.29)	23.33	74.44	170.41
Other comprehensive income attributable to				
Owners of the company	(3.12)	31.99	(1.73)	(12.51)
Non-controlling interest	(0.33)	(2.55)	0.48	(1.30)
Paid up equity share capital (face value of ₹ 5 each)	4,093.45	4,093.45	4,090.56	4,093.45
Other equity				
Earnings per equity share of ₹ 5 each (not annualised, excluding year end)				
Basic (₹)	5.41	7.80	1.83	19.81
Diluted (₹)	5.41	7.80	1.83	19.81

For Acutaas Chemicals Limited

Nareshkumar R Patel
Chairman & Managing Director
DIN: 00906232

Date: July 30, 2025
Place: Surat



Notes to the Unaudited Consolidated Financial Results for the quarter ended June 30, 2025

1. The above unaudited consolidated financial results for the quarter ended June 30, 2025, which includes the financial information of Acutaas Chemicals Limited (Formerly known as Ami Organics Limited) ("the Company") and its subsidiary entities namely Ami Organics Electrolytes Private Limited, Baba Advance Materials Limited and Baba Fine Chemicals (collectively "the group"), and its joint venture namely Ami Onco-Theranostics LLC, were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 30, 2025. The Statutory Auditors of the Company have carried out a limited review of the consolidated unaudited financial results for the quarter ended on June 30, 2025. Their limited review report does not have any modification.
2. The above unaudited consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.
3. As the Company operates in Single Segment only i.e. Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others. it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.
4. The Board of Directors of the Company at their meeting held on February 21 2025, and the Shareholders through postal ballot passed on March 26, 2025 have approved the sub-division/ split of each equity share of face value of Rs.10/- (Rupees Ten only) each, fully paid-up, into (two) equity shares having face value of Rs. 5/- (Rupees five only) each, fully paid-up. The record date for the said sub-division/ split was April 25, 2025. The basic and diluted EPS disclosed above have been adjusted to give effect to such sub-division/split in accordance with requirements under Ind AS 33, Earnings per share.
5. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Registrar of Companies, Ministry of Corporate Affairs has approved the following name changes:
 - Ami Organics Limited has been renamed Acutaas Chemicals Limited with effect from May 15, 2025. Consequently, the Memorandum of Association and Articles of Association of the Company stand altered to reflect this change.
 - Two wholly-owned subsidiary companies have also undergone a name change:
 - Baba Advance Materials Limited has been renamed Acutaas Advance Material Limited, effective July 17, 2025.
 - Ami Organics Electrolytes Private Limited has been renamed Acutaas Chemicals Electrolytes Private Limited, effective July 28, 2025.
6. In accordance with Regulation 30 read with Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Acutaas Advance Material Limited ("AAML") (formerly known as Baba Advance Materials Limited), wholly owned subsidiary company of Acutaas Chemicals Limited has entered into a joint venture agreement with J & Materials Co. Ltd., a South Korean Company, whereby BAML shall hold 75% of the share capital of the joint venture company Indichem Inc. ("JV Company") a South Korean Company and the remaining 25% of the share capital of the JV Company will be held by J & Materials Co. Ltd., effectively from June 27, 2025.
7. In accordance with Regulation 30 read with Schedule II of the Listing Regulations, Acutaas Chemicals Limited ("the Company") has on recommendation and approval of the Audit Committee & Board of Directors, made investment in Acutaas Advance Material Limited ("AAML") (formerly known as Baba Advance Materials Limited) up to an amount not exceeding Rs 49.99 crores by subscribing to 30,48,780 equity shares of Rs 10/- each, at a premium of Rs. 154/- per share by way of rights issue of AAML and further investment not exceeding Rs. 150 crores by way of loan or equity subscription or mix of both, in one or more tranches in AAML, wholly owned subsidiary of the Company.
8. The Company had issued fresh equity shares of ₹ 10/- each at a premium of ₹ 1,230/- per share aggregating ₹ 9,909.99 Lakh by way of preferential issue, which were allotted on May 31, 2024, and got listing and trading approval of BSE Limited and National Stock Exchange of India Limited effective from June 14, 2024, simultaneously.
The utilization of proceeds from Preferential Issue is summarized below:



(₹ in lakhs)				
S. No.	Item Heads	Projected Utilization of Proceeds as per the Offer Document	Amount utilized up to June 30, 2025	Unutilized amount as on June 30, 2025
1	Capital expenditure for electrolyte additives and/or allied business of the Company and/or its Subsidiaries	7,700.00	7,700.00	-
2	General Corporate Purpose	2,209.99	2,209.99	-
	Total	9,909.99	9,909.99	-

9. The previous periods/year's numbers have been regrouped/ rearranged wherever necessary to confirm the current period/year presentation.

10. The figures for the quarter ended March 31, 2025, are balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the financial year.

11. The results of the company are available at Company's website www.acutaas.com and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com where the shares of the Company are listed.

For and behalf of Board of Directors of
Acutaas Chemicals Limited
 (Formerly known as Ami Organics
 Limited)



Nareshkumar R. Patel
 Chairman & Managing Director
 DIN: 00906232

Date: July 30, 2025
 Place: Surat



Independent Auditor's Review Report on Unaudited Standalone Financial Results of Acutaas Chemicals Limited for the Quarter ended June 30, 2025 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Acutaas Chemicals Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Acutaas Chemicals Limited ('hereinafter referred to as 'the Company') for the quarter ended June 30, 2025 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Regulations)
2. This Statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') as amended, read with relevant rules issued thereunder ('Ind AS 34') and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.

Chartered Accountants

Firm's Registration No.: 105834W



Vikas Asawa

(Partner)

(Membership No.: 172133)

UDIN: 25172133BMIABE6317



Place: Mumbai

Date: July 30, 2025

Office: 1302/1303, Solaris One, Vijay Nagar, Opp. Teli Gali, Andheri (East), 400069

Head office: 10-11, Third Floor, Esplanade Building, 3 A K Naik Marg (Bestian Road), Near New Empire Cinema, Fort, CST, Mumbai 400 001
Tel.: +91-22-22077472/22072620, E-mail: info@maheshwariandco.in, Website: www.maheshwariandco.in



ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Standalone Unaudited Financial Results for the Quarter Ended June 30, 2025

(₹ in Lakhs, unless otherwise stated)

Particulars	Quarter Ended			Year Ended
	June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
	Unaudited	Unaudited	Unaudited	Audited
Income				
Revenue from operations	20,597.09	30,416.14	17,113.70	98,983.46
Other income	1,602.01	569.42	189.73	1,833.56
Total Income	22,199.10	30,985.56	17,303.43	100,817.02
Expenses				
Cost of materials consumed	10,317.71	16,321.40	10,464.04	56,684.02
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(654.23)	(197.87)	(381.59)	(1,864.56)
Employee benefits expense	2,440.25	2,261.00	1,845.64	8,094.72
Finance costs	61.96	38.33	437.27	585.74
Depreciation and amortization expense	746.21	655.65	562.14	2,404.52
Other expenses	3,394.50	3,625.86	2,555.81	13,555.05
Total expenses	16,306.40	22,704.37	15,483.31	79,459.49
Profit before exceptional items and tax	5,892.70	8,281.19	1,820.12	21,357.53
Exceptional items	-	-	-	-
Profit before tax	5,892.70	8,281.19	1,820.12	21,357.53
Tax expense				
Current tax	1,272.82	1,522.94	361.83	4,697.08
Deferred tax	155.26	473.57	86.70	705.83
Total tax expense	1,428.08	1,996.51	448.53	5,402.91
Profit for the period	4,464.62	6,284.68	1,371.59	15,954.62
Other comprehensive income				
Items that will not be reclassified to profit or loss				
Remeasurement of defined employee benefit plans	(3.65)	46.92	(2.31)	(14.59)
Tax impact on items that will not be reclassified to profit or loss	0.92	(11.81)	-	3.67
Total Other Comprehensive Income (net of tax)	(2.73)	35.11	(2.31)	(10.92)
Total comprehensive income for the period	4,461.89	6,319.79	1,369.28	15,943.70
Details of equity share capital				
Equity shares of face value Rs. 5/- each	4,093.45	4,093.45	4,090.56	4,093.45
Other equity				127,066.07
Earnings per equity share of ₹ 5/- each (not annualised, excluding year end)				
Basic (₹)	5.45	7.84	1.71	19.91
Diluted (₹)	5.45	7.84	1.71	19.91



For Acutaas Chemicals Limited


Nareshkumar R Patel
Chairman & Managing Director
DIN: 00906232

Date: July 30, 2025

Place: Surat

Notes to the Unaudited Standalone Financial Results for the quarter ended June 30, 2025

1. The above unaudited standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 30, 2025. The Statutory Auditors of the Company have carried out a limited review of the standalone unaudited financial results for the quarter ended on June 30, 2025. Their limited review report does not have any modification.
2. The above unaudited standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.
3. As the Company operates in Single Segment only i.e. Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others. it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.
4. The Board of Directors of the Company at their meeting held on February 21, 2025 and the Shareholders through postal ballot passed on March 26, 2025 have approved the sub-division/ split of each equity share of face value of Rs.10/- (Rupees Ten only) each, fully paid-up, into (two) equity shares having face value of Rs. 5/- (Rupees five only) each, fully paid-up. The record date for the said sub-division/ split was April 25, 2025. The basic and diluted EPS disclosed above have been adjusted to give effect to such sub-division/split in accordance with requirements under Ind AS 33, Earnings per share.
5. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to intimations dated April 16, 2025, April 17, 2025 and May 10, 2025, the Registrar of Companies, Ministry of Corporate Affairs, has approved the change in name of the Company from "Ami Organics Limited" to "Acutaas Chemicals Limited" with effect from May 15, 2025. Further, pursuant to the change of name of the Company, the Memorandum of Association and Articles of Association of the Company stands altered to the extent of the change of name of Company with effect from May 15, 2025.
6. Pursuant to Regulation 30 read with Schedule II of the Listing Regulations, Acutaas Chemicals Limited ("the Company") has on recommendation and approval of the Audit Committee & Board of Directors, made investment in Acutaas Advance Material Limited ("AAML") (formerly known as Baba Advance Materials Limited) up to an amount not exceeding Rs 49.99 crores by subscribing to 30,48,780 equity shares of Rs 10/- each, at a premium of Rs. 154/- per share by way of rights issue of AAML and further investment not exceeding Rs. 150 crores by way of loan or equity subscription or mix of both, in one or more tranches in AAML, wholly owned subsidiary of the Company.
7. The Company had issued fresh equity shares of ₹ 10/- each at a premium of ₹ 1,230/- per share aggregating ₹ 9,909.99 Lakh by way of preferential issue, which were allotted on May 31, 2024, and got listing and trading approval of BSE Limited and National Stock Exchange of India Limited effective from June 14, 2024, simultaneously.

The utilization of proceeds from Preferential Issue is summarized below:

(₹ in lakh)

S. No.	Item Heads	Projected Utilization of Proceeds as per the Offer Document	Amount utilized up to June 30, 2025	Unutilized amount as on June 30, 2025
1	Capital expenditure for electrolyte additives and/or allied business of the Company and/or its Subsidiaries	7,700.00	7,700.00	-
2	General Corporate Purpose	2,209.99	2,209.99	-
	Total	9,909.99	9,909.99	-

8. The previous periods/year's numbers have been regrouped/ rearranged wherever necessary to confirm the current period/year presentation.
9. The figures for the quarter ended March 31, 2025, are balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the financial year.



10. The results of the company are available at Company's website www.acutaas.com and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com where the shares of the Company are listed.



Date: July 30, 2025

Place: Surat



For and behalf of Board of Directors of
Acutaas Chemicals Limited
(Formerly known as Ami Organics
Limited)

Nareshkumar R. Patel
Chairman & Managing Director
DIN: 00906232